Parametrica Management LTD Fate Therapeutics Inc Transaction History

Parametrica Management LTD

  • $83.5 Million
  • Q3 2024

A detailed history of Parametrica Management LTD transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Parametrica Management LTD holds 18,472 shares of FATE stock, worth $49,504. This represents 0.08% of its overall portfolio holdings.

Number of Shares
18,472
Previous 18,472 -0.0%
Holding current value
$49,504
Previous $60,000 6.67%
% of portfolio
0.08%
Previous 0.08%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023
SELL
$4.24 - $11.12 $58,435 - $153,255
-13,782 Reduced 42.73%
18,472 $105,000
Q4 2022

Feb 07, 2023
BUY
$9.86 - $23.83 $178,357 - $431,060
18,089 Added 127.7%
32,254 $325,000
Q3 2022

Nov 02, 2022
SELL
$21.04 - $36.06 $15,232 - $26,107
-724 Reduced 4.86%
14,165 $318,000
Q2 2022

Jul 22, 2022
BUY
$17.78 - $42.39 $49,677 - $118,437
2,794 Added 23.1%
14,889 $371,000
Q1 2022

May 10, 2022
SELL
$29.67 - $60.28 $147,489 - $299,651
-4,971 Reduced 29.13%
12,095 $469,000
Q4 2021

Feb 15, 2022
SELL
$47.84 - $64.34 $136,056 - $182,982
-2,844 Reduced 14.28%
17,066 $999,000
Q3 2021

Nov 12, 2021
BUY
$59.27 - $95.73 $1.18 Million - $1.91 Million
19,910 New
19,910 $1.18 Million
Q1 2021

May 14, 2021
SELL
$72.16 - $117.4 $198,584 - $323,084
-2,752 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$38.09 - $100.95 $104,823 - $277,814
2,752 New
2,752 $250,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $260M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Parametrica Management LTD Portfolio

Follow Parametrica Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parametrica Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Parametrica Management LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email